GSK plc (GSK) Income Statement
GSK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsGSK revenue and net income
Where GSK's revenue goes
2025Each bar shows an amount and its share of revenue. GSK kept 17.5% of revenue as net income.
GSK profit margins
GSK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
GSK quarterly EPS vs estimates
GSK beat the analyst EPS estimate in 2 of the last 2 quarters. Next report: October 28, 2026 (estimate $1.40).
GSK income statement
| 2025 | |
|---|---|
| Revenue | $32.67B |
| Cost of revenue | $9.02B |
| Gross profit | $23.65B |
| Research & development | $7.53B |
| Sales, general & admin | $9.09B |
| Total operating expenses | $15.31B |
| Operating income | $8.34B |
| Interest income | $531.0M |
| Interest expense | $687.0M |
| Income before taxes | $7.40B |
| Income taxes | $1.11B |
| Net income | $5.72B |
| EBITDA | $10.40B |
| EPS (diluted) | $4.60 |
| Gross margin | 72.4% |
| Operating margin | 25.5% |
| Net margin | 17.5% |
| Dec '25 | Jun '25 | |
|---|---|---|
| Revenue | $8.62B | $7.99B |
| Cost of revenue | $2.66B | $2.17B |
| Gross profit | $5.96B | $5.82B |
| Research & development | $2.35B | $2.02B |
| Sales, general & admin | $2.64B | $2.14B |
| Total operating expenses | $4.46B | $3.80B |
| Operating income | $1.51B | $2.02B |
| Interest income | $150.0M | $136.0M |
| Interest expense | $174.0M | $184.0M |
| Income before taxes | $950.0M | $1.89B |
| Income taxes | $223.0M | $241.0M |
| Net income | $636.0M | $1.44B |
| EBITDA | $1.91B | $3.23B |
| EPS (diluted) | $0.70 | $1.24 |
| Gross margin | 69.2% | 72.9% |
| Operating margin | 17.5% | 25.3% |
| Net margin | 7.4% | 18.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in GSK's financial statements (latest annual report filed March 6, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
GSK financial results
In fiscal year 2025 (ended December 31, 2025), GSK reported revenue of $32.7 billion. It had net income of $5.7 billion, a net profit margin of 17.5%. Diluted earnings per share came to $4.60.
See the GSK stock overview for the latest quote and news, or the GSK chart for price history and technical indicators.
GSK income statement FAQ
What is GSK's annual revenue?
GSK reported total revenue of $32.7 billion for fiscal year 2025, which ended on December 31, 2025.
Is GSK profitable?
Yes. GSK reported net income of $5.7 billion in fiscal 2025, a net profit margin of 17.5%; its operating margin was 25.5%.
What is GSK's gross margin?
GSK's gross margin was 72.4% in fiscal 2025: for every $100 of revenue, GSK kept $72 after the direct cost of its products and services.
How much does GSK spend on research and development?
GSK spent $7.5 billion on research and development in fiscal 2025, 23.0% of revenue.
What are GSK's earnings per share?
GSK earned $4.60 per diluted share in fiscal 2025.
When will GSK report its next earnings?
GSK is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 before the market opens.
When does GSK's fiscal year end?
GSK's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 6, 2026.